Reduction in self-harming behaviour

Published Date: 19th July 2016

Publication Authors: Javed S

​

Abstract

No psychotropic drug is specifically licensed for the management of emotionally unstable borderline personality disorder. Prescribing ‘off-label’ places additional responsibilities on the prescriber and may increase liability if there are adverse effects. This case report describes a patient with borderline personality disorder who was started on zuclopenthixol decanoate with successful outcome in terms of reducing self-harming behaviour and impulsivity.

Javed Q; Chorghade, A; Javed, S; Pervez, Y. (2014).  Reduction in self-harming behaviour after zuclopenthixol decanoate . Progress in Neurology and Psychiatry. 18 (4), 23-27

« Back